---
title: "Shanghai RAAS Blood Products Gets Trial Approval for Blood Clotting Disorder"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/264390728.md"
description: "Shanghai RAAS Blood Products Gets Trial Approval for Blood Clotting Disorder"
datetime: "2025-11-05T09:30:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/264390728.md)
  - [en](https://longbridge.com/en/news/264390728.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/264390728.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/264390728.md) | [English](https://longbridge.com/en/news/264390728.md)


# Shanghai RAAS Blood Products Gets Trial Approval for Blood Clotting Disorder



### 相關股票

- [Shanghai RAAS (002252.CN)](https://longbridge.com/zh-HK/quote/002252.CN.md)

## 相關資訊與研究

- [RAAS Blood Products Gets Plasma Collection License for Fengzhen Tonglu Plasma Collection Station](https://longbridge.com/zh-HK/news/278489427.md)
- [SSY Gets China Nod for Production, Registration of Vitamin Injection](https://longbridge.com/zh-HK/news/279036594.md)
- [Hengrui Pharmaceuticals Gets Nod to Trial SHR-9803 for Injection](https://longbridge.com/zh-HK/news/278830096.md)
- [<![CDATA[FDA Approves Leucovorin Without a Clinical Trial for Cerebral Folate Transport Deficiency: Report ]]>](https://longbridge.com/zh-HK/news/278589943.md)
- [China Medical System says China approves Desidustat tablets for CKD anaemia](https://longbridge.com/zh-HK/news/279028848.md)